TIL

Instil Bio Inc. (TIL) | Rumor.io

Instil Bio

TIL

Attention (50-day avg)0%

Attention rank (50-day avg)#4,910

Bullish sentiment (50-day avg)0%

Price to earnings ratio-0.66

Market capitalization47.7M

Earnings per share-4.4

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-71.4M

Social

What share of all stock conversation is about TIL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 7

Instil Bio's subsidiary, Axion Bio, has discontinued clinical development of IMM2510/AXN-2510.
Instil Bio's stock price has fallen by 45.81% following the announcement.
Analysts and traders are expressing bearish sentiment towards Instil Bio's stock, citing concerns over its empty pipeline and lack of value.

Generated by AI

Sentiment

Of the messages about TIL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	25.64% -46.84
Bearish	—	—	—	74.36% +46.84

Bullish· Sep 16

Instil Bio's ($TIL) price target was raised to $120 from $40 at H.C. Wainwright, with the firm maintaining a Buy rating.
The analyst's updated model captures additional potential market niches for SYN-2510, a treatment that could become the next-generation version of Roche's Tecentriq.
Instil Bio's stock has seen significant gains, with a 800% increase in just 5 days, and is expected to continue its uptrend, potentially attracting more investors.

Bearish· Sep 16

$TIL faces a high risk of share dilution due to the potential need for additional funding for further trials, which could lead to a decrease in stock value.
Instil Bio's valuation is considered overly optimistic by some analysts, citing the challenges and costs associated with bringing a new drug to market.
$TIL's lack of revenue in the last 12 months, as reported by Yahoo Finance, has raised concerns about the legitimacy of the company's business model and the potential for a pump and dump scheme.

Generated by AI

Topics

Of the messages about TIL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0.56%
Announcements	—	—	—	91.62%
Controversies	—	—	—	6.7%
Earnings	—	—	—	0%
Macro	—	—	—	0.56%
Technical Analysis	—	—	—	0.56%

Announcements· Jan 6

Instil Bio's subsidiary Axion Bio has discontinued the clinical development of AXN-2510 and terminated its license agreement with ImmuneOnco, returning all rights to ImmuneOnco.
The company will retain a limited license solely to wind down clinical activities for AXN-2510 and AXN-27M, with no disclosed financial terms or exit payments.
Instil Bio's stock has fallen after the announcement, with shares temporarily halted following the news, as the company refocuses its resources on novel therapies.

Technical Analysis· Sep 13

The author has identified $TIL as a potentially difficult ticker to trade, requiring aggressive catching of bigger turns intraday.
The Weekly chart on $TIL shows a gap, and the author has discussed the anatomy of a trade with a final result of +1.8R across 4 trades.
The author is waiting for a wave to go through on $TIL, expecting a sell signal, and is also monitoring the EMAs on the ticker to trail stops and avoid giving back profits.

Generated by AI

Community

Of the messages about TIL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	57.72%
Newcomers	—	—	—	42.28%

Regulars· Sep 16

Instil Bio's (TIL) PT raised to $120 from $40 at HCW, indicating a significant increase in the company's stock value.
The company has announced a global registrational strategy for its PD-L1xVEGF bispecific antibody, SYN-2510/IMM2510, in non-small cell lung cancer and triple-negative breast cancer, which may lead to future developments and growth.
Instil Bio's stock price has been volatile, with a 10.87% drop at $79.06 in the last 20 minutes, and a short interest of 0.8%, which may be a concern for investors.

Newcomers· Jan 6

The company's clinical pipeline appears to have failed, with two drugs being handed back to their original owner, potentially ending Instil Bio's hopes for a refreshed clinical pipeline.
The stock is considered a balance-sheet special situation, with a conservative net asset value (NAV) of $6.5 per share, offering a potential ~100% upside in the near term.
The company's subsidiary has discontinued development of AXN-2510, and the license and collaboration agreement with ImmuneOnco has been terminated, potentially leading to the company refocusing resources and potentially ending its prospects for this asset.

Generated by AI

Also Discussed

Investors talking about TIL also mention

#	Name	Attention
1	OMIC - Singular Genomics Systems, Inc.	——
2	ACHL - Achilles Therapeutics plc	——
3	Summit Therapeutics Inc.SMMT	0.05%-0.04
4	Iovance Biotherapeutics Inc.IOVA	1.03%+0.91
5	Bicycle Therapeutics plc - ADRBCYC	0%0
6	Replimune Group, Inc.REPL	0%0
7	Fate Therapeutics Inc.FATE	0%new
8	JBDI Holdings LimitedJBDI	0%0
9	RDFN - Redfin Corporation	——
10	ATXS - Astria Therapeutics, Inc.	——

Instil Bio Inc.

Healthcare
Biotechnology

Instil Bio Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer. The company’s current work centers on tumor-infiltrating lymphocyte, or TIL, cell therapies designed to harness a patient’s own immune cells to attack solid tumors. Its pipeline also includes next-generation programs built around engineered TIL approaches and bispecific antibody candidates aimed at difficult-to-treat cancers. Instil Bio Inc. operates as a research-driven biotechnology business, combining cell therapy development, manufacturing expertise, and clinical-stage oncology programs to address areas of significant unmet medical need. Headquartered in Dallas, Texas, the company plays a specialized role in the oncology market through its focus on advanced immunotherapy platforms and novel therapeutic candidates.

Website

Location

3963 Maple Avenue

Dallas, TX, 75219

United States

Social

What share of all stock conversation is about TIL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 7

Instil Bio's subsidiary, Axion Bio, has discontinued clinical development of IMM2510/AXN-2510.
Instil Bio's stock price has fallen by 45.81% following the announcement.
Analysts and traders are expressing bearish sentiment towards Instil Bio's stock, citing concerns over its empty pipeline and lack of value.

Generated by AI

Sentiment

Of the messages about TIL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	25.64% -46.84
Bearish	—	—	—	74.36% +46.84

Bullish· Sep 16

Instil Bio's ($TIL) price target was raised to $120 from $40 at H.C. Wainwright, with the firm maintaining a Buy rating.
The analyst's updated model captures additional potential market niches for SYN-2510, a treatment that could become the next-generation version of Roche's Tecentriq.
Instil Bio's stock has seen significant gains, with a 800% increase in just 5 days, and is expected to continue its uptrend, potentially attracting more investors.

Bearish· Sep 16

$TIL faces a high risk of share dilution due to the potential need for additional funding for further trials, which could lead to a decrease in stock value.
Instil Bio's valuation is considered overly optimistic by some analysts, citing the challenges and costs associated with bringing a new drug to market.
$TIL's lack of revenue in the last 12 months, as reported by Yahoo Finance, has raised concerns about the legitimacy of the company's business model and the potential for a pump and dump scheme.

Generated by AI

Topics

Of the messages about TIL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0.56%
Announcements	—	—	—	91.62%
Controversies	—	—	—	6.7%
Earnings	—	—	—	0%
Macro	—	—	—	0.56%
Technical Analysis	—	—	—	0.56%

Announcements· Jan 6

Instil Bio's subsidiary Axion Bio has discontinued the clinical development of AXN-2510 and terminated its license agreement with ImmuneOnco, returning all rights to ImmuneOnco.
The company will retain a limited license solely to wind down clinical activities for AXN-2510 and AXN-27M, with no disclosed financial terms or exit payments.
Instil Bio's stock has fallen after the announcement, with shares temporarily halted following the news, as the company refocuses its resources on novel therapies.

Technical Analysis· Sep 13

The author has identified $TIL as a potentially difficult ticker to trade, requiring aggressive catching of bigger turns intraday.
The Weekly chart on $TIL shows a gap, and the author has discussed the anatomy of a trade with a final result of +1.8R across 4 trades.
The author is waiting for a wave to go through on $TIL, expecting a sell signal, and is also monitoring the EMAs on the ticker to trail stops and avoid giving back profits.

Generated by AI

Community

Of the messages about TIL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	57.72%
Newcomers	—	—	—	42.28%

Regulars· Sep 16

Instil Bio's (TIL) PT raised to $120 from $40 at HCW, indicating a significant increase in the company's stock value.
The company has announced a global registrational strategy for its PD-L1xVEGF bispecific antibody, SYN-2510/IMM2510, in non-small cell lung cancer and triple-negative breast cancer, which may lead to future developments and growth.
Instil Bio's stock price has been volatile, with a 10.87% drop at $79.06 in the last 20 minutes, and a short interest of 0.8%, which may be a concern for investors.

Newcomers· Jan 6

The company's clinical pipeline appears to have failed, with two drugs being handed back to their original owner, potentially ending Instil Bio's hopes for a refreshed clinical pipeline.
The stock is considered a balance-sheet special situation, with a conservative net asset value (NAV) of $6.5 per share, offering a potential ~100% upside in the near term.
The company's subsidiary has discontinued development of AXN-2510, and the license and collaboration agreement with ImmuneOnco has been terminated, potentially leading to the company refocusing resources and potentially ending its prospects for this asset.

Generated by AI

Instil Bio

Social

Jan 7

Sentiment

Bullish· Sep 16

Bearish· Sep 16

Topics

Announcements· Jan 6

Technical Analysis· Sep 13

Community

Regulars· Sep 16

Newcomers· Jan 6

News

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Also Discussed

Instil Bio Inc.

Company Information

Location

News

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Also Discussed

Social

Jan 7

Sentiment

Bullish· Sep 16

Bearish· Sep 16

Topics

Announcements· Jan 6

Technical Analysis· Sep 13

Community

Regulars· Sep 16

Newcomers· Jan 6